Collecting samples to study response to mavacamten in hypertrophic cardiomyopathy
Part of Heart & circulation clinical trials.
This study collects blood samples and medical information from people with obstructive hypertrophic cardiomyopathy to learn why the medication mavacamten works differently in different people. The goal is to understand how genes and other factors influence treatment response, which may help personalize care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy, with a significant blockage of blood flow from the heart.
- You should have symptoms like breathlessness or chest pain (NYHA class II or III) despite taking standard heart medicines like beta-blockers or calcium channel blockers.
- Your heart's pumping function must be at least 55% (measured by an echocardiogram).
- You must have had a blood test to check your CYP2C19 gene before starting or while taking mavacamten.
- You must not be pregnant, breastfeeding, or under legal guardianship.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at adults with a heart condition called obstructive hypertrophic cardiomyopathy. It tracks what happens after they start taking the medicine mavacamten, to learn more about its effects and how it works in real life.
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
This study looks at whether adjusting the dose of mavacamten based on heart function helps people with obstructive hypertrophic cardiomyopathy feel better and have fewer side effects. It is for people who are already on mavacamten and want to see if a personalized dose approach works.
This study tracks the safety of Mavacamten in people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow). It helps doctors understand how the drug works in everyday use in Japan.
This study looks at whether people with hypertrophic cardiomyopathy who are doing well on mavacamten can slowly reduce or stop their beta-blocker medication. The goal is to find out if it's safe and helps patients manage with fewer medications.
This study looks at how a drug called mavacamten, which relaxes the heart muscle, works in people with obstructive hypertrophic cardiomyopathy. It uses genetic testing to try to predict who will respond best to the drug.
Hear when a new Obstructive Hypertrophic Cardiomyopathy (oHCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.